Darwin Global Management, Ltd.
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Darwin Global Management, Ltd. reported 9 stock positions worth $859.5 million. Its top holding was Cytokinetics (CYTK) at 28.6% of the portfolio, followed by Insmed (INSM, 27.6%) and Vaxcyte (PCVX, 19.1%). Compared with Q1 2024, it opened 5 new positions, sold out of 8, added to 1 and reduced 3. The biggest buy was a new position in Cytokinetics (CYTK) and the biggest sale an exit from Nuvalent Class A (NUVL).
- Most Recent 13F
- Q2 2026
- Location
- ST. HELIER, Y9
- CIK
- 0001839209
- Portfolio Value
- $859.5M (Q2 2024)
- SEC Filing
- 0001892688-24-000095 ↗ filed Aug 14, 2024
Holdings Value
Holdings 9 stocks · $859.5M
| CYTK Cytokinetics Inc. | 28.63% | 4,575,558 | $246.1M | New |
| INSM Insmed Inc. | 27.58% | 3,541,095 | $237.1M | New |
| PCVX Vaxcyte Inc. | 19.07% | 2,080,946 | $163.9M | Reduce -24.4% |
| GERN Geron Corp. | 12.35% | 23,915,480 | $106.2M | New |
| KROS Keros Therapeutics Inc. | 8.00% | 1,525,902 | $68.8M | Add +6.3% |
| CRBP Corbus Pharmaceuticals Holdi | 1.66% | 325,140 | $14.3M | New |
| SYRE Spyre Therapeutics Inc. | 1.19% | 452,040 | $10.3M | Reduce -4.5% |
| RNAM Avidity Biosciences Inc. | 0.94% | 200,000 | $8.1M | New |
| ELEV Elevation Oncology Inc. | 0.56% | 1,916,290 | $4.8M | Reduce -17.9% |
Portfolio Sells Q1 2024 → Q2 2024
| NUVL Nuvalent Inc. Class A | Sold out | 0.00% | −14.36 |
| BHVN Biohaven Ltd. | Sold out | 0.00% | −10.75 |
| ALPN Alpine Immune Sciences Inc. | Sold out | 0.00% | −10.46 |
| BEAM Beam Therapeutics Inc. | Sold out | 0.00% | −9.32 |
| APGE Apogee Therapeutics Inc. | Sold out | 0.00% | −7.36 |
| PCVX Vaxcyte Inc. | Reduce -24.4% | 19.07% | −5.94 |
| XNCR Xencor Inc. | Sold out | 0.00% | −3.27 |
| TRML Tourmaline Bio Inc. | Sold out | 0.00% | −1.42 |
| MRK Merck & Co. Inc. | Sold out | 0.00% | −1.40 |
| SYRE Spyre Therapeutics Inc. | Reduce -4.5% | 1.19% | −1.20 |
| ELEV Elevation Oncology Inc. | Reduce -17.9% | 0.56% | −1.03 |
Portfolio Buys Q1 2024 → Q2 2024
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 5 | $3.8B | RVMD, INSM, BLTE, ABVX, ROIV |
| Q1 2026 | 6 | $3.8B | INSM, BLTE, ABVX, RVMD, ROIV |
| Q4 2025 | 6 | $4.9B | INSM, BLTE, ABVX, CDTX, WVE |
| Q3 2025 | 5 | $3.6B | INSM, UTHR, ABVX, CDTX, QURE |
| Q2 2025 | 5 | $2.4B | INSM, VRNA, CDTX, MRUS, ALLO |
| Q1 2025 | 3 | $1.5B | INSM, VRNA, ALLO |
| Q4 2024 | 6 | $1.1B | INSM, JAZZ, VRNA, GERN, KROS |
| Q3 2024 | 5 | $1.2B | INSM, PCVX, GERN, KROS, SMMT |
| Q2 2024 | 9 | $859.5M | CYTK, INSM, PCVX, GERN, KROS |
| Q1 2024 | 12 | $751.2M | PCVX, NUVL, KROS, BHVN, ALPN |